New stroke drug LT3001 tested in small trial – could it be safer?

NCT ID NCT04091945

Completed Disease control Sponsor: Lumosa Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase IIa trial tested a single dose of LT3001, a new drug, in 24 people who had an acute ischemic stroke within the past 24 hours. The main goal was to see if the drug causes dangerous bleeding in the brain compared to a placebo. Researchers also looked for early signs that the drug might help improve outcomes. The study is complete, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LT3001
What this could lead to: If successful, this could point toward a new treatment option for acute ischemic stroke that may help restore blood flow with a lower risk of bleeding.
What could go wrong: This is an early Phase IIa trial with only 24 participants, so results may not apply broadly. The main safety concern is bleeding in the brain, and the drug may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Chattanooga Center for Neurologic Research

Chattanooga, Tennessee, 37403, United States
China Medical University Hospital

Taichung, Taiwan
JFK Neuroscience Institute, JFK Medical Center

Edison, New Jersey, 08837, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan
Linkou Chang Gung Memorial Hospital

New Taipei City, Taiwan
Taichung Veterans General Hospital

Taichung, Taiwan
Taipei Medical University - Shuang Ho Hospital

New Taipei City, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan
The Ohio State University - Wexner Medical Center

Columbus, Ohio, 43210, United States
University of Kentucky Chandler Medical Center

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.